Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $8.82, for a total value of $17,640.00. Following the sale, the chief executive officer now directly owns 14,615,662 shares in the company, valued at approximately $128,910,138.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.67, for a total value of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total value of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Price Performance

NASDAQ ZYXI opened at $8.83 on Friday. The stock has a market capitalization of $281.24 million, a P/E ratio of 58.87 and a beta of 0.53. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The business’s fifty day moving average is $8.15 and its two-hundred day moving average is $9.00. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm’s revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. On average, research analysts forecast that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Trading of Zynex

Several large investors have recently added to or reduced their stakes in the company. Gladius Capital Management LP raised its stake in Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after purchasing an additional 1,742 shares during the period. Principal Financial Group Inc. raised its stake in Zynex by 10.4% during the 2nd quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock valued at $182,000 after purchasing an additional 1,846 shares during the period. Cim LLC raised its stake in Zynex by 6.1% during the 2nd quarter. Cim LLC now owns 43,581 shares of the company’s stock valued at $406,000 after purchasing an additional 2,508 shares during the period. American Century Companies Inc. raised its stake in Zynex by 10.1% during the 2nd quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock valued at $290,000 after purchasing an additional 2,864 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Zynex by 1.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock valued at $1,797,000 after purchasing an additional 2,954 shares during the period. 29.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on ZYXI shares. Royal Bank of Canada dropped their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright upped their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.